Head to Head Contrast: Immunome (NASDAQ:IMNM) & Arbutus Biopharma (NASDAQ:ABUS)

Immunome (NASDAQ:IMNM) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Volatility & Risk

Immunome has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Insider and Institutional Ownership

44.6% of Immunome shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Immunome and Arbutus Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94 million	346.47	-$212.39 million	($2.53)	-8.37
Arbutus Biopharma	$14.08 million	65.71	-$33.50 million	$0.79	5.91

Arbutus Biopharma has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Immunome and Arbutus Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1	1	12	0	2.79
Arbutus Biopharma	0	1	1	0	2.50

Immunome currently has a consensus target price of $34.25, indicating a potential upside of 61.79%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 7.07%. Given Immunome’s stronger consensus rating and higher probable upside, equities analysts plainly believe Immunome is more favorable than Arbutus Biopharma.

Profitability

This table compares Immunome and Arbutus Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Arbutus Biopharma	84.22%	90.98%	82.34%

Summary

Arbutus Biopharma beats Immunome on 8 of the 14 factors compared between the two stocks.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.